Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates.

Yadav DB, Maloney JA, Wildsmith KR, Fuji RN, Meilandt WJ, Solanoy H, Lu Y, Peng K, Wilson B, Chan P, Gadkar K, Kosky A, Goo M, Daugherty A, Couch JA, Keene T, Hayes K, Nikolas LJ, Lane D, Switzer R, Adams E, Watts RJ, Scearce-Levie K, Prabhu S, Shafer L, Thakker DR, Hildebrand K, Atwal JK.

Br J Pharmacol. 2017 Nov;174(22):4173-4185. doi: 10.1111/bph.14021. Epub 2017 Oct 6.

PMID:
28859225
2.

Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.

Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y, Wildsmith KR, Couch JA, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK, Ramanujan S, Joseph S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.

3.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

4.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

5.

CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, Pyatkivskyy Y, Wildsmith KR, Kasten T, Mathers P, Dancho M, Lennox C, Smith BE, Gilberto D, McLoughlin D, Holder DJ, Stamford AW, Yarasheski KE, Kennedy ME, Savage MJ, Bateman RJ.

J Neurosci. 2014 Jun 11;34(24):8336-46. doi: 10.1523/JNEUROSCI.0540-14.2014.

6.

Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.

Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA.

Mol Neurodegener. 2014 Jun 6;9:22. doi: 10.1186/1750-1326-9-22.

7.

Evidence for impaired amyloid β clearance in Alzheimer's disease.

Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE.

Alzheimers Res Ther. 2013 Jul 12;5(4):33. doi: 10.1186/alzrt187. eCollection 2013. Review.

8.

Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.

Liu X, Wong H, Scearce-Levie K, Watts RJ, Coraggio M, Shin YG, Peng K, Wildsmith KR, Atwal JK, Mango J, Schauer SP, Regal K, Hunt KW, Thomas AA, Siu M, Lyssikatos J, Deshmukh G, Hop CE.

Drug Metab Dispos. 2013 Jul;41(7):1319-28. doi: 10.1124/dmd.112.050864. Epub 2013 Apr 12.

9.

In vivo human apolipoprotein E isoform fractional turnover rates in the CNS.

Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, Holtzman DM, Bateman RJ.

PLoS One. 2012;7(6):e38013. doi: 10.1371/journal.pone.0038013. Epub 2012 Jun 4.

10.

Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling.

Basak JM, Kim J, Pyatkivskyy Y, Wildsmith KR, Jiang H, Parsadanian M, Patterson BW, Bateman RJ, Holtzman DM.

Mol Neurodegener. 2012 Apr 18;7:14. doi: 10.1186/1750-1326-7-14.

11.

Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.

Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ.

J Neurosci. 2010 May 12;30(19):6743-50. doi: 10.1523/JNEUROSCI.1381-10.2010.

12.

Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry.

Wildsmith KR, Han B, Bateman RJ.

Anal Biochem. 2009 Dec 1;395(1):116-8. doi: 10.1016/j.ab.2009.07.049. Epub 2009 Aug 3.

13.

Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans.

Elbert DL, Mawuenyega KG, Scott EA, Wildsmith KR, Bateman RJ.

J Proteome Res. 2008 Oct;7(10):4546-56. doi: 10.1021/pr800386u. Epub 2008 Sep 6.

14.

Metabolism of myeloperoxidase-derived 2-chlorohexadecanal.

Wildsmith KR, Albert CJ, Anbukumar DS, Ford DA.

J Biol Chem. 2006 Jun 23;281(25):16849-60. Epub 2006 Apr 11.

15.

Myeloperoxidase-derived 2-chlorohexadecanal forms Schiff bases with primary amines of ethanolamine glycerophospholipids and lysine.

Wildsmith KR, Albert CJ, Hsu FF, Kao JL, Ford DA.

Chem Phys Lipids. 2006 Feb;139(2):157-70. Epub 2006 Jan 6.

PMID:
16417904
16.

Characterization of alkylacyl, alk-1-enylacyl and lyso subclasses of glycerophosphocholine by tandem quadrupole mass spectrometry with electrospray ionization.

Hsu FF, Turk J, Thukkani AK, Messner MC, Wildsmith KR, Ford DA.

J Mass Spectrom. 2003 Jul;38(7):752-63.

PMID:
12898655
17.

Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein.

Thukkani AK, Albert CJ, Wildsmith KR, Messner MC, Martinson BD, Hsu FF, Ford DA.

J Biol Chem. 2003 Sep 19;278(38):36365-72. Epub 2003 Jul 17.

Supplemental Content

Loading ...
Support Center